evipedia.ai
← Back to Review

Audit: QRS - Phenylpropylaminopentane for Health & Longevity

Audit conducted on 04/09/2026 16:30 using AI4L / Opus 5

Iterations

Summary

Items Count
Total 93
Passed 85
Failed 0
N/A 8
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Spot-checked every populated span against the ER: protocol cells vs ER Therapeutic Protocol, time cells vs ER Practical Considerations “Time to effect”, gates vs ER Key Interactions & Contraindications, tiers vs ER benefit/risk headings, markers and cadence vs ER Monitoring Protocol & Defining Success.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 “Unknown in humans”, “Never given to a person in a published study”, “Human scaling is not reliable”, “No chronopharmacology study exists” all mirror the ER’s hedging.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindications remain contraindications; cautions remain cautions; every benefit and risk stays at the ER’s Speculative tier.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Stop items come only from the ER’s “Populations who should avoid” list; caution items only from the ER interaction bullets; no modifying factor is promoted into a gate.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, NCT numbers, author names, or brand names appear anywhere in the QRS.
1.6 The QRS does not introduce new attributions. 🟢 No laboratory, author, or organisation is named.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Matches the ER’s restrained, evidence-absence-forward framing.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 States what is measured, what is inferred, and what is unknown, giving the reader the basis for their own decision.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 No prescriptive instructions; monitoring targets are presented as reference ranges carried from the ER.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No imperative “take”, “start”, “consult” phrasing in the document’s own voice.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 All cells are declarative statements of the ER record.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns anywhere in the file.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms retained are load-bearing and carry the ER’s own glosses (e.g., “Sympathomimetic (adrenaline-mimicking)”).
2.8 Information is presented in a concise and very compact manner 🟢 Every cell is a fragment or a single short sentence; gate items are stripped to the key fact.
2.9 It DOES NOT address the reader directly 🟢 Confirmed by full-text search for “you”/”your”; none present.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Content assumes a reader evaluating an unapproved compound, with monitoring targets tighter than clinical cut-offs.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Twice-daily blood pressure, electrocardiogram at four weeks, and serial laboratory panels are presented without hedging on burden.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 No simplification toward a general-population reader.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 At-a-glance leads with the absence of any human exposure, the decisive fact for a self-experimenting reader.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “anti-aging” does not appear; the title uses “Health & Longevity” and the benefit item uses “geroprotection”.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 “myocardial infarction”, “tachyarrhythmia”, “hepatic impairment”, “corrected QT interval” used throughout; the at-a-glance plain wording is required by 7.4.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All headings verified verbatim at lines 445, 490, 538, 563, 581, 609, 633, 757; column headers at 637–639; the rendered tier label “Speculative: “ is unchanged.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 34 template variable names present; the repeatable marker_#_* and qualitative_item_# rows are expanded to marker_1–8 and qualitative_item_1–5.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Diff against the template shows the head, CSS block, website="evidence_review", website="audit", website="full_review" spans, and the footer disclaimer are byte-identical.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No ER section drawn on by the QRS is empty; the empty benefit/risk tiers are governed by items 12.5 and 13.5, which forbid empty-state phrasing.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 “No established human protocol”, “Animal reference dosing”, “Best time of day”, “Time to effect”, and all five qualitative labels are carried verbatim from the ER’s bold labels.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Every label with an ER counterpart is verbatim; marker names match the ER biomarker table exactly.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 Full-text search returns no emoji; the ER’s tier emoji and the “⚠️ Conflicted” marker are not carried over.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Each section is condensed against its ER source (11 contraindications reduced to single clauses, 7 interactions to name-plus-examples, 8 biomarker rows to three short columns, cadence to two sentences).

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14; the doctype is line 1 and nothing precedes the comment.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening “—” at line 3, closing “—” at line 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; no metadata value is repeated in the header or body.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 Line 4: er_filename: phenylpropylaminopentane_2026-0904-1340_Opus_ER.md.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 Line 6: qrs_creation_date: 2026-0904-1523.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 Line 7: qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus” is a single word with no version or qualifier.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 Line 8: qrs_creator_ai_fullname: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” — nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 Line 9 matches the file’s actual name on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 Line 22: “Phenylpropylaminopentane for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 Line 417: “Phenylpropylaminopentane for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 Line 421: “09/04/2026”, matching qrs_creation_date 2026-0904-1523.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Line 425: “Opus 5”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header is the template structure only; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses the Conclusion’s four load-bearing points: purpose as a probe, absence of human exposure, rodent findings, contested mechanism.
7.2 [at_a_glance] is no longer than 60 words 🟢 51 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Maps to ER lines 412 (“built to prove a point”, learning and apathy in rats, no human dose or safety record) and 414–416 (contested mechanism, independent testing placing it among ordinary stimulants).
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms; “catecholaminergic activity enhancer”, “TAAR1”, “dopamine transporter” and similar are all avoided in favour of plain wording.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No study, author, or year is named.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No IC50 values or numeric results appear.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All 11 items trace to the ER’s “Populations who should avoid Phenylpropylaminopentane” list (ER lines 254–266).
8.2 [stop_items] represent the Contraindications from the ER 🟢 Complete one-to-one coverage of the ER list, including the MAOI bullet flagged as an absolute contraindication.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 11 <li> elements inside the span (lines 566–576).
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Trailing rationale stripped, e.g. ER “Anyone under 25, in whom the compound’s own developmental hypothesis predicts no headroom for enhancement” → “Age under 25”. No dash-trailing clauses remain.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “(seated blood pressure ≥160/100 mmHg)”, “(<12 months)”, “(marked limitation, or symptoms at rest)”, “(Child-Pugh Class B or C)” all preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation inside parentheses in this section.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 The ER identifies 11 such populations and the section is correctly populated, not empty.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All 7 items trace to the ER interaction bullets (ER lines 240–252).
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 All 7 caution-level ER bullets present; the MAOI bullet (“Absolute contraindication”) is correctly excluded here and carried in the stop gate instead.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 7 <li> elements inside the span (lines 584–599).
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Mechanistic rationale dropped throughout; ER’s “Other interventions — anaesthesia and surgery” reduced to “Anaesthesia and surgery” with no dash clause.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Every drug-example list retained, trimmed to names only, e.g. “(sertraline, venlafaxine, tricyclics)”, “(pseudoephedrine, phenylephrine, oxymetazoline)”.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation inside parentheses in this section.
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 The ER identifies eight interaction bullets and the section is correctly populated, not empty.
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 All three cells trace to ER Therapeutic Protocol bullets (ER lines 288, 294, 296).
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Absence of any validated human protocol, the only published dose reference (rodent), and timing — the three aspects that determine what a reader could act on.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER Therapeutic Protocol section contains eleven bullets; all three action sets are used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All nine spans populated; labels verbatim, values and subs condensed from the matching ER bullets.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 The ER’s “Time to effect” bullet states exactly three: unknown in humans, behavioural effect within a single session, transmitter-release change at 30 minutes. All three are carried.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Every ER benefit is Speculative with no stated magnitude; the order runs from the human-relevant fact to the behavioural finding to the neurochemical one, mirroring the ER’s own ordering of decision relevance.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct aspects are present in the ER; all three sets are used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All nine spans populated from ER line 341; no placeholder text remains.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 The six speculative items match the six ER Speculative 🟨 sub-headings one to one.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present at lines 540, 543, 546, 549.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each item is the bare heading, e.g. “geroprotection” from “Geroprotection via Restored Enhancer Signalling”; no supporting sentences carried.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in the benefits list; the ER’s “stereotypy (repetitive, purposeless movement)” gloss is not carried.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 benefits_high, benefits_medium, benefits_low each carry style="display: none" with an HTML comment recording the ER basis; no empty-state text renders.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 The six speculative items match the six ER Speculative 🟨 sub-headings one to one.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present at lines 611, 614, 617, 620.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each item is the bare heading; the IC50 values and class read-across reasoning from the ER are not carried.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses in the risks list; the ER’s “⚠️ Conflicted” marker on abuse liability is also correctly omitted per 4.4.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 risks_high, risks_medium, risks_low each carry style="display: none" with an HTML comment recording the ER basis; no empty-state text renders.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Rows and cadence trace to the ER Monitoring Protocol & Defining Success table and paragraph (ER lines 369–380).
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All eight ER biomarkers present with matching ranges: seated blood pressure, resting heart rate, QTc, ALT, prolactin, TSH, fasting glucose, body weight.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Line 747: twice daily for two weeks then weekly, electrocardiogram at four weeks, liver panel and blood count at eight weeks then every three to six months — matching ER line 369.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 The five items trace to the ER’s qualitative-marker bullets (ER lines 384–388).
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 Sleep quality, cognitive clarity, energy and drive, mood and irritability, and appetite are all present with the ER’s bold labels verbatim.

Issues 04/09/2026 16:30

Pass rate 100.00%. No issues found.

Issues 04/09/2026 16:23

  1. 9.5 — Dropped plain-language gloss: The ER’s parenthetical gloss in “Sympathomimetic (adrenaline-mimicking) over-the-counter medicines” (ER line 244) is dropped entirely at QRS line 587 rather than trimmed, leaving the jargon term unglossed.

Fixes 04/09/2026 16:23

  1. 9.5 — Restored sympathomimetic gloss: Reinstated the ER’s parenthetical gloss in the Key Interactions item, changing “Sympathomimetic over-the-counter medicines” to “Sympathomimetic (adrenaline-mimicking) over-the-counter medicines”.

Issues 04/09/2026 16:18

  1. 12.3 — Mechanistic clause in benefit item: In [benefits_speculative] (line 554) the item “geroprotection via restored enhancer signalling” retains the ER heading’s mechanistic clause; 12.3 bars mechanistic explanations, leaving “geroprotection” as the key fact.

Fixes 04/09/2026 16:18

  1. 12.3 — Mechanistic clause in benefit item: Trimmed the final [benefits_speculative] item from “geroprotection via restored enhancer signalling” to “geroprotection”, removing the mechanistic clause.

Issues 04/09/2026 16:09

  1. 1.1 — Unsupported route on 30-minute finding: [time_3_sub] (QRS lines 528–530) reads “Earliest measured signal, following subcutaneous injection in rats”, but the ER (line 341) states only “Rodent transmitter-release changes appeared 30 minutes after injection” — neither the subcutaneous route nor the “earliest measured” characterisation is stated in the ER for that fact.
  2. 4.5 — Sheet overflows one A4 page: The content stack exceeds the printable A4 height by roughly 80%, driven by an 11-item Contraindications gate that wraps to ~19 lines, an 8-row Monitoring table with full-sentence “Why” cells, five Qualitative items carrying their ER explanatory clauses, and multi-line protocol sub-texts; none of these were condensed to the per-section budget.

Fixes 04/09/2026 16:09

  1. 1.1 — Unsupported route on 30-minute finding: Replaced [time_3_sub] “Earliest measured signal, following subcutaneous injection in rats.” with “Transmitter-release change measured after injection in rodents.”, which is literally supported by ER line 341.
  2. 4.5 — Protocol sub-lines condensed: Shortened [action_2_sub] to “Subcutaneous; motility rose at 2 mg/kg. Human scaling is not reliable; no allometric conversion published.” and trimmed [action_3_sub] to “Evening dosing predicted to impair sleep onset.”
  3. 4.5 — Contraindication parenthetical trimmed: Shortened the heart-failure staging parenthetical from “(marked limitation of activity, or symptoms at rest)” to “(marked limitation, or symptoms at rest)”, preserving the NYHA class per 8.5.
  4. 4.5 — Monitoring cells and cadence condensed: [marker_8_target] reduced to “None; track change from baseline”, [marker_4_why] to “Clearance route unmapped; liver stress”, and [monitoring_cadence] trimmed of its redundant qualifiers.
  5. 4.5 — Qualitative descriptions condensed: All five qualitative items had their trailing ER explanatory clauses compressed (e.g., “deterioration is the earliest warning sign” → “earliest warning sign”; “an early marker of nutritional risk” → “an early nutritional marker”), with the ER bold labels left verbatim.

Note on 4.5: the condensation above reduces the rendered stack, but the one-page budget remains under pressure from content that the checklist mandates in full — all eight measurable biomarkers (14.2), all five qualitative markers (15.2), all eleven contraindications with their qualifiers (8.2 / 8.5), and all seven interactions with their named drug lists (9.2 / 9.5).

Issues 04/09/2026 16:02

  1. 11.4 — Time cell sub restates its value: time_3_sub at line 529 reads “Measured 30 minutes after injection.”, which adds nothing to time_3_value “30 minutes” (line 525) under the label “Transmitter release in rodents”; the sub-line carries no independent content.
  2. 1.1 — Body-weight target drops “change from”: marker_8_target at line 738 reads “None established; track own baseline”, whereas the ER (line 380) states “No established target; track change from the individual’s own baseline” — the compression changes the instruction and leaves “own” without an antecedent.

Fixes 04/09/2026 16:02

  1. 11.4 — Time cell sub restates its value: Replaced time_3_sub “Measured 30 minutes after injection.” with “Earliest measured signal, following subcutaneous injection in rats.”, so the sub-line now adds route and species framing instead of repeating the “30 minutes” value.
  2. 1.1 — Body-weight target drops “change from”: Changed marker_8_target from “None established; track own baseline” to “None established; track change from own baseline”, restoring the ER’s delta-tracking instruction and the antecedent for “own”.

Issues 04/09/2026 15:55

  1. 1.1 — NYHA qualifier reworded: The heart-failure contraindication at line 569 states “(symptoms on light activity or at rest)”, whereas the ER (line 259) reads “(marked limitation of activity, or symptoms at rest)”; “light activity” is a clinical gloss with no literal support in the source.

Fixes 04/09/2026 15:55

  1. 1.1 — NYHA qualifier restored to ER wording: Changed the heart-failure contraindication parenthetical from “(symptoms on light activity or at rest)” to the ER’s own “(marked limitation of activity, or symptoms at rest)”.

Issues 04/09/2026 15:47

  1. 4.5 — Content exceeds one A4 page: Estimated rendered height is roughly 1.7 A4 pages. The compressible elements still carry ER prose at full length — the eight Monitoring “Why” cells, the five Qualitative Assessment items, and the three Protocol sub-cells each wrap to two or more lines where one would carry the same fact.

Fixes 04/09/2026 15:47

  1. 4.5 — Monitoring “Why” cells condensed: Shortened markers 3–8 to single-line statements, e.g. “Detects the arrhythmia risk that stimulant-class compounds can create” to “Detects stimulant-class arrhythmia risk” and “Appetite suppression is the most likely nutritional harm and shows up as weight loss first” to “Appetite suppression shows first as weight loss”.
  2. 4.5 — Body weight target shortened: Changed marker 8 target from “No established target; track change from own baseline” to “None established; track own baseline”, keeping the ER’s no-target statement.
  3. 4.5 — Qualitative Assessment items condensed: All five items trimmed to one rendered line each, e.g. “Whether meals are being skipped without hunger” to “Meals skipped without hunger”, with every ER fact retained.
  4. 4.5 — Protocol cells condensed: Moved the dosing route out of action 2’s value (“1–5 mg/kg subcutaneously in rodents” to “1–5 mg/kg in rodents”, with “Subcutaneous;” opening the sub-cell) and trimmed the action 1 and action 3 sub-cells.
  5. 4.5 — Time-to-effect sub trimmed: Reduced time 3’s sub from “Rodent transmitter-release changes appeared 30 minutes after injection.” to “Measured 30 minutes after injection.”, since label and value already carry the rest.
  6. 4.5 — Heart failure qualifier tightened: Shortened the New York Heart Association parenthetical from “(marked limitation of activity, or symptoms at rest)” to “(symptoms on light activity or at rest)”, trimming rather than dropping the severity qualifier.
  7. 4.5 — Monitoring cadence condensed: Removed redundant wording (“for the first two weeks” to “for two weeks”, “Electrocardiogram repeats at four weeks” to “Electrocardiogram at four weeks”) with no change to the schedule.

Issues 04/09/2026 15:39

  1. 1.1 — NYHA qualifier reworded: The heart-failure contraindication at QRS line 570 renders the severity gloss as “(symptoms at rest or on minimal activity)”, whereas the ER (line 259) states “(marked limitation of activity, or symptoms at rest)”; “minimal activity” is not supported by the ER text.

Fixes 04/09/2026 15:39

  1. 1.1 — NYHA qualifier restored to ER wording: The heart-failure contraindication parenthetical was changed from “(symptoms at rest or on minimal activity)” to the ER’s verbatim “(marked limitation of activity, or symptoms at rest)”.

Issues 04/09/2026 15:34

  1. 8.5 — Heart-failure staging gloss dropped: The QRS contraindication at line 570 reads “Heart failure, New York Heart Association Class III or IV” but drops the ER’s parenthetical “(marked limitation of activity, or symptoms at rest)” (ER line 259), which is the staging detail a reader needs to judge whether the class applies to them.

Fixes 04/09/2026 15:34

  1. 8.5 — Heart-failure staging gloss restored: Changed the contraindication from “Heart failure, New York Heart Association Class III or IV” to “Heart failure, New York Heart Association Class III or IV (symptoms at rest or on minimal activity)”, restoring the ER’s staging qualifier in condensed form.

Issues 04/09/2026 15:28

  1. 1.1 — Unsupported “largest signal” ranking: [time_2_sub] (lines 517-518) asserts that “learning and retention facilitation is the animal record’s largest signal”, a magnitude ranking that appears nowhere in the ER, which lists it as one of six co-equal Speculative benefits.

Fixes 04/09/2026 15:28

  1. 1.1 — Unsupported “largest signal” ranking: Trimmed [time_2_sub] to “Suggesting acute rather than cumulative action.”, removing the clause “learning and retention facilitation is the animal record’s largest signal” that the ER does not support.